A new long-acting GLP-1 derivative KTP ameliorates hyperglycemia and dyslipidemia and improves pancreas and fatty liver in db/db mice by YanXia Sang et al.
   
 
© The Author(s) 2013. This article is published with open access at Springerlink.com csb.scichina.com   www.springer.com/scp 
                      
*Corresponding author (email: tzth@jnu.edu.cn) 
Article 
Biochemistry & Molecular Biology July 2013  Vol.58  No.20: 24472453 
 doi: 10.1007/s11434-013-5915-y  
A new long-acting GLP-1 derivative KTP ameliorates hyperglycemia 
and dyslipidemia and improves pancreas and fatty liver in db/db mice 
SANG YanXia, ZHOU TianHong*, LI HongJian, RAN YanHong, JIANG DeQi, ZHENG Fei, 
CHEN Ying, WANG CongFeng & ZOU Xin 
College of Life Science and Technology, Jinan University, Guangzhou 510632, China 
Received January 30, 2013; accepted March 27, 2013; published online June 5, 2013 
 
Glucagon-like peptide-1 (GLP-1) is a polypeptide incretin hormone that glucose-dependently promotes the secretion and synthesis 
of insulin. However, its half-life is extremely short. To enhance its half-life, we developed a long-acting GLP-1 derivative KTP 
with controlled release, designed on the basis of another GLP-1 derivative GP62. The kinetics and bioactivity of KTP were evalu-
ated in Sprague Dawley (SD) rats. Long-term treatment of KTP was performed in db/db mice. Mice were treated twice daily with 
subcutaneous injections of KTP (1.2 mg/kg body weight), Exendin-4 (0.1 mg/kg body weight) or vehicle (phosphate buffered 
saline (PBS), pH 7.4) for 60 d. KTP had a longer half-life, as well as further increasing the secretion and production of insulin and 
reducing blood glucose concentrations, than GP62. Long-term treatment with KTP also induced anorexia, decreased water and 
food intake, decreased weight gain, improved blood glucose and blood lipid and ameliorated pancreatic damage and fatty liver in 
db/db mice. 
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Glucagon-like peptide 1 (GLP-1) is an important glucose 
dependent incretin hormone secreted by L-cells in the gas-
trointestinal tract [1−3]. GLP-1 reduces blood glucose con-
centration via glucose-dependent stimulation of insulin se-
cretion [4]. GLP-1 also delays gastric emptying [5,6] and 
has been shown to directly stimulate the growth and prolif-
eration of  cells [7]. Although GLP-1 has anti-diabetic 
potential [8−14], its native form, has a biological half-life of 
only a few minutes (<2 min) because of its very rapid deg-
radation in plasma by dipeptidyl peptidase IV (DPPIV) 
[15,16]. Its transient lifetime has limited the use of GLP-1 
to treat non-insulin-dependent diabetes mellitus (NIDDM).  
Efforts to improve the pharmacokinetics of GLP-1 have 
included structural modifications, coadministration of com-
petitive inhibitors and the use of various delivery systems 
[17,18]. Recently, a promising protease-based controlled 
release strategy was reported [19]. GP62 polypeptide, a de-
rivative of GLP-1, was designed according to this strategy 
and was found to slowly and continuously release bioactive 
GLP-1 through protease hydrolysis. Subcutaneously admin-
istered GP62 reduced blood glucose concentrations and 
acted over 10 h in GK rats. However, GLP-1 acted only for 
1.5 h. 
GP62 has a sequence of LPHSHRAHSLPPFNPRGP- 
(GLP-1) and contains three function domains, an albumin- 
binding domain (ABD, LPHSHRAHSLPP), a protease- 
cleavable linker (LK, FNPRGP) and bioactive GLP-1. LK 
is recognized and cleaved by thrombin and DPPIV. In vivo, 
GP62 can associate with serum albumin through ABD, en-
hancing its half-life in circulation. Dissociating from serum 
albumin, GP62 is hydrolyzed orderly by thrombin and DPPIV 
in the blood and releases coupled GLP-1 slowly.  
To further improve the controlled release of GP62, Arg(R)- 
Gly(G) in the LK of GP62 was replaced by Lys(K)-Thr(T), 
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generating a new GLP-1 derivative polypeptide, KTP, with 
the sequence LPHSHRAHSLPPFNPKTP-(GLP-1). We ev-  
aluated the kinetics and bioactivity of KTP in SD rats and 
its long-term effects on food and water intake, body weight, 
blood glucose, blood lipids, pancreas and fatty liver in the 
db/db mouse model of type 2 diabetes. 
1  Materials and methods 
1.1  Materials  
Male SD rats (280−300 g) were obtained from the Animal 
Center of Guangdong Medical Experiments, and db/db mice 
(25−30 g) were purchased from ARLMATE Ltd. The ani-
mals were housed in stainless steel hanging cages (three to 
four per cage) under standard laboratory conditions (12:12 
light:dark cycle, temperature 25−27°C, humidity 50%−60%), 
with free access to food and water. All animals were moni-
tored for 2 weeks prior to any experimental procedures.   
Unless otherwise indicated, all reagents were of the 
highest quality commercially available. 
KTP and GP62 were prepared in the Biochemistry and 
Molecular Biology Laboratory (Jinan University). The gene 
encoding KTP was cloned into E. coli BL21 (DE3) and ex-
pressed in fusion protein form following induction by iso-
propyl -D-1-thiogalactopyranoside. The fusion protein was 
purified by Ni-NTA affinity chromatography, hydrolyzed 
with formic acid to remove tag peptide, and again purified 
by Ni-NTA affinity chromatography and HPLC. Mass spec-
trometry analysis showed a KTP purity of 96.9%. GA62 
was prepared similarly, yielding a purity of 97.3%. 
Exendin-4 (HOR-269) was purchased from ProSpec- 
Tany TechnoGene Ltd. 
1.2  Experimental design 
(1) Kinetics of plasma KTP.  Two groups of SD rats 
(n=8 per group) were each injected subcutaneously with 
KTP and GP62 (1.2 mg/kg body weight each). Blood from 
the tail vein was collected into heparinized capillary tubes 
before injection and at 1, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 
28, 36 and 48 h after injection. Samples were kept on ice 
until plasma was separated by centrifugation. The sample 
times were based on the preliminary experiments and were 
designed to determine the time to the maximum plasma 
concentration (Tmax) of KTP and GP62. 
(2) Insulinotropic activity test.  Eighteen male SD rats 
were fasted overnight, randomized into 3 groups (n=6 per 
group) and each injected subcutaneously with KTP (1.2 mg/kg 
body weight), GP62 (1.2 mg/kg body weight) or an equal 
volume of vehicle (PBS, pH 7.4) 30 min before glucose 
loading. At time 0, each rat was orally administered glucose 
(2 g/kg, 50% glucose solution) by gavage. Blood samples 
were taken from the tail vein into heparinized capillary 
tubes at 30, 0, 15, 30, 45, 60, 75, 90, 120 and 150 min and 
kept on ice until the plasma was separated by centrifugation. 
(3) Hypoglycemic effect.  Three groups of db/db mice 
(n=8 per group) each were subcutaneously injected with 
KTP (1.2 mg/kg body weight), GP62 (1.2 mg/kg body 
weight) or an equal volume of vehicle, with dose volumes 
based on pretreatment body weight. Blood samples were 
collected from the tail vein for blood glucose analysis be-
fore and 1, 3, 5, 7, 9, 12 and 24 h after injection. 
(4) Long-term treatment experiment of db/db mice with 
KTP.  Three groups of db/db mice (n=8 per group) each 
received two daily subcutaneous injections, at 08:30 and 
19:30, of KTP (1.2 mg/kg body weight), Exendin-4 (0.1 
mg/kg body weight) or vehicle for 60 d. Dose volumes were 
based on pretreatment body weights and ranged from 
0.1−0.2 mL per mouse. Food and water intake were meas-
ured daily, and the animals were weighed weekly between 
09:00 and 11:00. Following a 2-day drug-free recovery 
period, oral glucose tolerance test (OGTT) was performed, 
and blood was obtained by puncture of the orbital venous 
plexus with glass capillary tubes. The animals were eu-
thanized, and the pancreas and liver of each were rapidly 
removed and stored in buffered formalin (4%). 
1.3  Oral glucose tolerance test  
Following an overnight fast (16 h), each animal was admin-
istered glucose (2 g/kg, 50% glucose solution) into the 
stomach using a gavage needle. Blood was taken from the 
tail vein at 0, 5, 10, 20, 30, 60, 120 and 180 min. 
1.4  Measurement of blood parameters 
Blood glucose concentrations were measured by one touch 
Ultra (Johnson & Johnson, USA). Blood samples for kinetic 
analysis or insulin measurement were centrifuged at 2000×g 
for 10 min at 4°C, and the resulting plasma samples were 
placed into cryotubes, which were stored at less than 18°C 
pending analysis. Plasma concentrations of KTP and GP62 
were determined by double sandwich ELISA using a cap-
turing antibody (ABS 046-03, BioPorto, Denmark), detect-
ing antiserum (rabbit anti-LK of KTP or GP62, Baiaotai 
Biological Technology Co., Ltd., China) and rat anti-rabbit 
IgG-HRP (4065-05, SouthernBiotech, USA). Plasma insulin 
concentrations were estimated using Ultra Sensitive Rat 
Insulin ELISA Kits (90060, Crystal Chem, USA) according 
to the manufacturer’s protocol.  
Blood lipids were analyzed by a biochemical autoana-
lyzer (Wako, Japan).  
1.5  Histology   
Tissue sections were prepared and stained with hematoxylin- 
eosin (H&E) as described [20]. After sacrifice, the pancreas 
and liver of each animal were fixed overnight in 4% para-
formaldehyde, fractionated, dehydrated, embedded and  
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sectioned at 5 m. The sections were stained with H&E and 
examined by light microscopy (Olympus BX51 Microscope, 
Japan). 
Immunohistochemical staining was performed as de-
scribed [21]. Antigen retrieval was performed using citrate 
buffer (pH 6.0), and endogenous peroxidases were quenched 
with 3% hydrogen peroxide. Sections of pancreas were in-
cubated orderly with rabbit anti-insulin antibody (15848-1- 
AP, Proteintech Group, USA) for 2 h and with a biotinylat-
ed secondary antibody (4010-08, SouthernBiotech, USA) 
for 1 h, with expression detected by reaction with horseradish 
peroxidase-streptavidin-biotin complex and 3,3’-diamino-     
benzidine tetrachloride (DAB). All sections were counter-
stained with Mayer’s hematoxylin. 
1.6  Statistical analysis  
Data are expressed as mean±standard error (SE), with be-
tween groups differences assessed using Student’s t-test or 
one- or two-way ANOVA, as appropriate. All statistical 
analyses were assessed using SPSS version 11.5 software. A 
P value<0.05 was considered statistically significant.  
2  Results 
2.1  Kinetics of plasma KTP 
The plasma concentration of KTP was higher than that of 
GP62 within 28 h after administration. The maximum plasma 
concentration (Cmax) was higher (43.18 nmol/L vs 30.56 
nmol/L) and the Tmax was longer (4 h vs 3 h) for KTP than 
for GP62. The terminal elimination half-lives (t1/2) of KTP 
and GP62, calculated with the method of residuals, were  
7.8 h and 5.7 h, respectively (Figure 1). 
2.2  Insulinotropic and hypoglycemic effects of KTP 
Both KTP and GP62 increased insulin secretion and produc-     
tion significantly in SD rats, with KTP being more active 
than GP62. Time to maximum plasma concentration of in-
sulin was somewhat later for KTP than for GP62, although 
both were earlier than vehicle (Figure 2). 
Blood glucose concentrations of db/db mice treated with 
a single dose of KTP or GP62 were significantly lower than 
those of vehicle-treated mice within 24 h or 12 h after ad-
ministration (P<0.05 each). Importantly, blood glucose 
concentrations differed significantly in KTP and GP62- 
treated mice beginning 7 h after administration (P<0.05) 
(Figure 3). 
2.3  Long-term treatment of db/db mice with KTP 
(1) Changes in food and water intake.  Following 60 
days of treatment with KTP or Exendin-4, the food and water 
intake of db/db mice were significantly lower than before  
 
Figure 1  Mean plasma concentrations of KTP and GP62 versus time 
profiles after a single dose of subcutaneous injection in SD rats. The plas-
ma concentration of KTP was significantly higher than that of GP62 within 
28 h after administration. *P<0.05 versus GP62. 
 
Figure 2  Insulinotropic activities of KTP and GP62. Rats received sub-
cutaneous injection with KTP (1.2 mg/kg body weight), GP62 (1.2 mg/kg 
body weight) or an equal volume of vehicle and after 30 min, were orally 
administered glucose (2 g/kg, 50% glucose solution). *P<0.05 versus vehi-
cle, #P<0.05 versus GP62. 
 
Figure 3  Mean blood glucose concentration versus time profiles after a 
single dose of subcutaneous injection with KTP (1.2 mg/kg body weight), 
GP62 (1.2 mg/kg body weight) or an equal volume of vehicle in db/db 
mice. *P<0.05 versus vehicle, #P<0.05 versus GP62. 
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treatment (P<0.05), differences not observed in vehicle- 
treated mice. Moreover, after 60 d, the food and water in-
take were significantly lower in mice treated with KTP or 
Exendin-4 than in vehicle-treated mice (P<0.05). Food and 
water intake, however, did not differ significantly in mice 
treated with KTP and Exendin-4 (Figure 4 (a) and (b)). 
(2) Changes in body weight.  The body weights of all 
db/db mice increased continuously throughout the entire 
experiment. Beginning during week 5, however, the body 
weight of mice treated with KTP or Exendin-4 was signifi-
cantly lower than that of mice treated with vehicle (P<0.05) 
(Figure 5(a)). After 60 d, the body weight gain of db/db 
mice treated with KTP or Exendin-4 was significantly less 
than that of vehicle-treated mice (P<0.05) (Figure 5(b)), but 
there were no significant differences between mice treated 
with KTP and Exendin-4 (Figure 5 (a) and (b)).  
(3) Changes in blood glucose and lipid.  Compared with 
vehicle-treated mice, the blood glucose concentrations of 
mice treated with KTP (P<0.05) and Exendin-4 (P<0.05) were  
 
Figure 4  The effects of KTP long-term treatment on food (a) and water 
(b) intake in db/db mice. After 60-d treatment, food and water intake were 
significantly less than before treatment (a, P<0.05) and that of vehi-
cle-treated mice (b, P<0.05) in KTP-treated mice and Exendin-4-treated 
mice. There was no significant difference between before and after treat-
ment in vehicle-treated mice. a, P<0.05 versus before treatment; b, P<0.05 
versus vehicle. 
significantly lower at 5, 10, 60, 120, and 180 min after glu-
cose loading, with no differences between the KTP and Ex-
endin-4 groups. However, all three groups had similar blood 
glucose concentrations at 20 and 30 min (Figure 6).  
 
Figure 5  The effects of KTP long-term treatment on body weight (a) and 
body weight gain (b) in db/db mice. The body weight of KTP-treated and 
Exendin-4-treated mice were significantly lower than that of vehicle- 
treated mice (P<0.05). After 60 d, the body weight gain of KTP-treated and 
Exendin-4-treated mice were significantly less than that of vehicle-treated 
mice (P<0.05). *P<0.05 versus vehicle. 
 
Figure 6  The blood glucose concentration during oral glucose tolerance 
test performed in db/db mice treated with KTP, GP62 or vehicle. *P<0.05 
versus vehicle. 
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Both total cholesterol (TC) and triglyceride (TG) con-
centrations were significantly lower in db/db mice treated 
with KTP or Exendin-4 than in the vehicle-treated mice 
(P<0.05 each), but no differences in TC and TG concentra-
tions between the KTP and the Exendin-4. High density 
lipoprotein cholesterol (HDL) and low density lipoprotein 
cholesterol (LDL) concentrations were similar in all three 
groups (Table 1).  
(4) Morphological changes in pancreas and liver.  More 
and more severe pathological changes were observed in 
mice treated with vehicle than in mice treated with KTP or 
Exendin-4. Pancreatic acini showed disordered arrangements, 
disorganized structures and atrophy, with smaller nuclei and 
less cytoplasm. Capillary vessels of pancreas islets were 
seriously congested and the density of islet cells decreased 
(Figure 7(a)). Although pathological changes were observed 
in mice treated with KTP or Exendin-4, they were fewer 
and less severe than in vehicle-treated mice (Figure 7(b) and 
(c)). More and denser insulin secretion granules, with deep-
er staining, were observed in mice treated with KTP or Ex-
endin-4 than with vehicle (Figure 7(d)–(f)). 
The livers of all mice were yellow in color with fatty 
particles on the surface. However, the liver surfaces of mice 
treated with vehicle were more yellow, greasy and rough 
than those of KTP or Exendin-4-treated mice. Moreover, the 
livers of vehicle-treated mice were larger than those of mice 
treated with KTP or Exendin-4.  
The livers of vehicle-treated mice showed complete dis-
appearance of hepatic cords, along with severe hydropic 
degeneration, fatty infiltration and atrophic nucleoli in most 
hepatic cells, which were irregularly arranged and swollen. 
Additionally, some hepatic cells seemed to be vacuoles with 
a cytoskeleton but without a nucleus (Figure 8 (a)). The 
pathologic changes observed in mice treated with KTP or  
Table 1  Changes in blood lipid after long-term treatment a) 
Group TC (mmol/L) TG (mmol/L) HDL (mmol/L) LDL (mmol/L) 
KTP 4.0016±0.1784* 0.9655±0.0794* 2.0817±0.0653 0.3050±0.0436 
Exendin-4 3.8321±0.2429* 0.8400±0.0867* 1.9750±0.0879 0.2850±0.0347 
Vehicle 4.9917±0.2243 1.3633±0.0824 1.9433±0.1124 0.3367±0.0278 
a) *P<0.05 versus vehicle 
 
Figure 7  H&E staining (a)–(c) and immunohistochemical staining (d)–(f) on paraffin sections of pancreas in db/db mice treated with vehicle (a) and (d), 
KTP (b) and (e) or Exendin-4 (c) and (f). 
 
Figure 8  H&E staining (a)–(c) on paraffin sections of livers in db/db mice treated with vehicle (a), KTP (b) or Exendin-4 (c). 
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Exendin-4 were less severe (Figure 8 (b) and (c)).  
3  Discussion 
Since thrombin hydrolyzes the amido bond at the C termi-
nus of Arg (R) or Lys (K), it can recognize and cleave the 
LK of GP62 on the C terminus of Arg (R). Moreover, it is 
more active in cleaving at Arg(R) than at Lys (K) [22]. 
DPPIV has the unique ability to cleave N-terminal Xxx 
(X)-Pro (P) dipeptides from protein molecules, with its hy-
drolytic activity affected by Xxx (X) [23]. To further im-
prove the controlled release of GP62, Arg (R) and Gly (G) 
in its LK (FNPRGP) were replaced by Lys (K) and Thr (T), 
respectively, generating a new GLP-1 derivative KTP. The 
amino acid substitutions may decrease the ability of thrombin 
and DPPIV to cleave the LK, slowing the release of GLP-1 
from KTP. Our results suggested that these substitutions 
prolonged the half-life of KTP. Moreover, a single dose of 
KTP was more active than a single dose of GP62 in pro-
moting the secretion and production of insulin and reducing 
blood glucose concentration, and showed continuous activ-
ity over 24 h. Taken together, these findings showed that the 
release of GLP-1 from KTP was better controlled than from 
GP62. Although the two amino acid substitutions doubtless 
played an important role in determining the lifetime of KTP, 
the contribution of each to hydrolysis by thrombin and 
DPPIV remains unclear.  
Although several GLP-1 derivatives have been prepared 
[19], their in vivo activity, resulting from hydrolysis by 
thrombin and DPPIV, remains unclear. We found that long- 
term (60 d) treatment with KTP had therapeutic effects on 
type 2 diabetes in db/db mice.  
Type 2 diabetes mellitus is a disorderly metabolic endo-
crine disease that accompanies obesity, hyperglycemia, hy-
perlipidemia, damaged pancreas, and fatty liver. Our find-
ings indicated that treatment with KTP could alleviate all of 
these symptoms of type 2 diabetes.  
In contrast to subcutaneous administration, a continuous 
intravenous drip of native GLP-1 significantly decreased 
food and water intake in Wister rats fed a high-fat diet [24], 
but these effects required high doses of GLP-1 because of 
its transient half-life. We found, however, that two daily 
subcutaneous injections of KTP significantly reduced food 
and water intake in db/db mice, affecting changes in body 
weight. Weight gain was lower in mice treated with KTP or 
Exendin-4 than vehicle. Moreover, in contrast to the effects 
of NN2211 (a long-acting GLP-1 derivative) on body weight 
loss in Wister rats [25], the body weight of all db/db mice 
continuously increased throughout the entire treatment pe-
riod, a difference that may be due to differences in the ani-
mal models tested.  
Hyperglycemia and dyslipidemia are typical symptoms 
of diabetes in db/db mice. Long-term treatment with KTP 
markedly improved glucose tolerance in db/db mice within 
15 min and after 1 h after glucose loading. Thus, KTP en-
hanced the first phase of insulin secretion and the second 
phase of insulin synthesis and secretion. Treatment with 
KTP also significantly decreased the concentrations of blood 
TG and TC in db/db mice. The changes of glucose tolerance 
and blood lipid might be related to the inhibition of food 
and water intake and pancreas improvements. We found, 
however, that serum HDL and LDL concentrations were 
similar in mice administered KTP and vehicle, which may 
be because of the relatively short treatment or the physio-
logical characteristics of the animal model.  
The pancreas and liver of db/db mice aged over 5 weeks 
are usually abnormal. Treatment with KTP may alleviate 
the deterioration of the pancreas by enhancing the synthesis 
and secretion of insulin, thus reducing the toxic effects of 
hyperglycemia on the pancreas. Furthermore, we found that 
KTP ameliorated fatty liver in db/db mice. Thus, KTP may 
act via two mechanisms: reducing blood lipid concentration 
by inhibiting food intake and enhancing endogenous lipid 
metabolism by improving the function of the pancreas  
islets.  
4  Conclusions 
Long-term administration of KTP induced anorexia, re-
duced food intake, had a good effect on weight gain, im-
proved blood glucose tolerance and lipid concentrations and 
ameliorated pancreas damage and fatty liver in db/db mice. 
KTP may therefore affect the development of type 2 diabe-
tes and may be a promising new treatment in patients with 
this condition.  
The authors are grateful to Li YueQin for kind discussion and suggestions 
which improve our results. 
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